Effects of Chinese herbal medicine in combination with mitomycin C on gastric cancer cells by unknown
Kuo et al. Biomarker Research  (2014) 2:26 
DOI 10.1186/s40364-014-0026-8RESEARCH Open AccessEffects of Chinese herbal medicine in combination
with mitomycin C on gastric cancer cells
Che-Chang Kuo1, Jian-Jung Chen2, James Y Tsai3 and Chung-Tsen Hsueh3*Abstract
Chinese herbal medicine (CHM) is frequently used by cancer patients in Chinese community. It remains largely
unknown about the interaction between CHM and chemotherapeutic agents. Herein, we evaluated 3 commonly
used CHM formulas for cancer patients: Bu-Zhong-Yi-Qi-Tang (BZYQT), Bao-Yuan-Tang (BYT), and Ju-Yuan-Jian (JYJ).
We examined the effects of these 3 formulas in human gastric cancer cells MKN-74, in terms of cytotoxicity and
apoptosis induction when used alone or in combination with mitomycin C (MMC). Cytotoxicity was determined by
tetrazolium dye colorimetric assay. The 10% inhibitory concentration of CHM was used in this study. Cells were first
exposed to CHM or phosphate buffered saline (as control) for 48 h. Then MMC at final concentration of 0.25 μg/ml
was added to media for another 24-h. Among these 3 CHM formulas, BZYQT showed the most pronounced effect
in augmenting MMC-induced cytotoxicity. The viability of MKN-74 cells was decreased to 43.1% when treated
with BZYQT and MMC, compared to 94.9% with MMC alone. We subsequently examined apoptosis induction by
quantitative florescent microscopy and single-strand DNA enzyme-linked immunosorbent assay, and found
BZYQT did not enhance MMC-induced apoptosis. Our findings indicate BZYQT in combination with MMC induces cell
death in gastric cancer cells via non-apoptotic mechanism. Our results provide a rationale for further investigation in
the interaction of CHM and anti-cancer treatment.
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There has been an increasing trend for cancer patients to
take alternative medicine with standard treatment [1,2].
Alternative medicine is used by many cancer patients with
intentions to improve their health and decrease the side
effects from anti-cancer treatment. The most common
form of alternative medicine used by cancer patients in
Taiwan and China is Chinese herbal medicine (CHM)
[3-5]. In Taiwan, it has been shown that more than 50% of
cancer patients are taking CHM [6,7].
Qi-invigorating herbs such as Ginseng, Astragalus,
Glycyrrhiza and Atractylodes are commonly prescribed
CHM for cancer patients in Chinese community during
their cancer treatment [8,9]. In preclinical studies, these
CHM have been shown to exhibit immunomodulatory
effects, and in some instances even anti-cancer activity.
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However, it is not known whether these CHM formula-
tions interact with cancer treatment such as chemother-
apy. In this study, we investigated the effects of CHM on
gastric cancer cells, and the interaction between CHM
and mitomycin C (MMC) in terms of cytotoxicity and
apoptosis induction on gastric cancer cells.Methods
Cell culture and drug treatment
Early-passage human gastric cancer MKN-74 cells were
established and characterized as described previously
[10,11]. All the cultures were maintained in standard
MEM media supplemented with 100 units/ml penicillin,
100 μg/ml streptomycin and 20% heat inactivated normal
calf serum (Gibco) at 37?C in a humidified atmosphere of
5% CO2. Cells were checked for mycoplasma contamin-
ation at least every 6 months and consistently tested
negative. MMC, MTT ([3-(4,5-dimethylthiazole-2-yl)-
2,5-diphenyl tetrazolium bromide] and bisbenzimide
trihydrochloride (Hoechst 33258) were purchased fromis an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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For drug treatment, exponentially growing MKN-74 cells
were seeded into 96-well culture plate at 2.5 ? 10 3 cells
per 200 μl of media, and allowed to adhere overnight. The
combination treatment was performed with CHM given
for 48 h followed by the addition of MMC for another
24 h. In the control group, phosphate buffered saline
(PBS) was used instead of CHM.
Preparation of CHM extract
Three formulations of Qi-invigorating CHM were used
and obtained from Koda Pharmaceutical (Taoyuan County,
Taiwan). Bu-Zhong-Yi-Qi-Tang (BZYQT) contains 10
species of medicinal plants [12]. Bao-Yuan-Tang (BYT)
contains 4 species of medicinal plants including Radix
Ginseng (root of Panax ginseng C.A. MEY), Radix
Glycyrrhizae Uralensis (root of Glycyrrhiza uralensis
FISCHER), Cortex Cinnamonomi Cassiae (cortex of
Cinnamomum cassia PRESL), and Radix Astragali Mem-
branaceus (root of Astragalus membranaceus BUNGE).
Ju-Yuan-Jian (JYJ) contains 5 species of medicinal plants
including Radix Ginseng (root of Panax ginseng C.A.
MEY), Radix Glycyrrhizae Uralensis (root of Glycyrrhiza
uralensis FISCHER), Radix Astragali Membranaceus (root
of Astragalus membranaceus BUNGE), Rhizoma Cimicifu-
gae (root and rhizome of Cimicifuga foetida L.), and
Rhizoma Astractylodis Macrocephalae (Root and rhi-
zome of Atractylodes macrocephala KOIDZUMI). The
hot-water extract of CHM was prepared, and concen-
trated to 1 g/ml in distilled water. The extract of CHM
was further dissolved in PBS with the final concentra-
tion of 100 mg/ml. The insoluble ingredients were spun
down by centrifugation at 1200 ? g for 30 min. The
supernatant was sequentially passed through 0.45-μm
and 0.22-μm filters for sterilization, then aliquoted and
stored at −20?C.
Cell viability assay
After drug treatment, cells were assayed for viability
using MTT colorimetric method [13]. In brief, MTT
(5 mg/ml) at 10% volume of culture media was added to
each well, and cells were incubated for another 3 h at
37?C. Then supernant was removed, and 200 μl of acidic
isopropanol was added to each well to dissolve forma-
zan. Spectrophotometrical absorbance at 570 nm and
690 nm wavelengths was measured with a microplate
reader. Background absorbance of plate at 690 nm was
subtracted from the 570 nm measurement.
Quantitative fluorescent microscopy
As previously described, the quantitative fluorescent mi-
croscopy method for apoptosis determination involves
staining with Hoechst 33258 of condensed chromatin,
which characterizes the cells undergoing apoptosis [14,15].After trypsinization, adherent and non-adherent cells
were washed with PBS, fixed in 3% paraformaldehyde,
and then incubated at room temperature for 10 min.
After removing fixative, the cells were washed with PBS,
resuspended in 20 μl PBS containing 8 μg/ml of Hoechst
33258, and incubated at room temperature for 15 min.
Aliquots of the cells (10 μl) were placed on glass slides
coated with 3-amino-propyl-triethoxysilane, and dupli-
cate samples of 400 cells each were counted and scored
for the incidence of apoptotic chromatin condensation
using an Olympus BH-2 fluorescence microscope.
Single-strand DNA enzyme-linked immunosorbent assay
(ELISA)
The apoptosis was quantitatively by a single-strand
DNA ELISA kit (Roche). Briefly, 104 cells were seeded
in 96-well culture plate and allowed to adhere over-
night. After drug treatment, the plates were centrifuged
at 200 ? g for 5 min and culture medium was removed.
Subsequently, 200 μl of 80% methanol in PBS as fixative
was added to each well, and plates were incubated at
room temperature for 30 min. After fixative was re-
moved, the plates were dried by floating in water bath at
37?C for 20 min. Then 50 μl of formamide was added to
each well to denature DNA, and the plates were incu-
bated in an oven at 75?C for 20 min. Afterwards plates
were cooled down in refrigerator at 4?C for 5 min. Sub-
sequently, formamide was replaced with 200 μl of 3%
non-fat dried milk in each well, and plates were incu-
bated at 37?C for 1 h to block non-specific binding sties.
Then each well was replaced with 100 μl of a mixture of
primary antibody against single-strand DNA (MAb F7-26)
and secondary antibody with peroxidase-conjugated
antimouse IgM for 30 min; washed three times with
PBS; incubated with peroxidase substrate before detec-
tion of absorbance in an ELISA plate reader at 405 nm.
Statistical analysis
Statistical analyses were performed by the Bonferroni
t-test method after analysis of variance. A p value less
than 0.05 was considered significant for all tests. Regres-
sion analysis was used to calculate half maximal inhibitory
concentration (IC50) and 10% inhibitory concentration
(IC10) values. Data were reported as a mean of 3 experi-
ments with ? standard deviation.
Results
Cytotoxic effect of CHM on MKN-74 cell
At first, we studied the cytotoxic effect of 3 commonly
used CHM formulas for cancer patients on MKN-74 cells.
Cells were treated with CHM for 72 h, and the cell viabil-
ity was measured by MTT assay. As shown in Table 1, the
IC50 for BZYQT, BYT and JYJ was 2.4 ? 0.6 mg/ml, 3.9 ?
0.8 mg/ml, and 1.8 ? 0.4 mg/ml, respectively. The IC 10
Figure 1 Effect of chinese herbal medicine formulas on the
cytotoxicity induced by MMC. MKN-74 cells were treated with IC10
concentration of 3 Chinese herbal medicine formulas (BZYQT, BYT
and JYJ) for 48 h. Then 0.25 μg/ml MMC was added for another 24 h.
Cell survival was quantified by MTT assay. Each value was determinate
as the percentage of untreated control group. Values were expressed
as mean ? SD from three separate experiments. ** P <0.01 compared
with untreated control group.
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0.1 mg/ml, and 0.68 ? 0.1 mg/ml, respectively.
Effect of CHM on MMC-induced cytotoxicity
MKN-74 cells were treated with PBS as control or various
CHM at IC10 concentration for 48 h first. Then MMC
(0.25 μg/ml) was added to CHM for another 24 h of incu-
bation before assaying for cell viability. This sequence of
CHM for 48 h followed by combination of CHM and
MMC for 24 h demonstrated significant cytotoxicity on
MKN-74 cells. Treatment of BZYQT, BYT or JYJ with
MMC resulted in cell viability of 43.1 ? 3.7%, 65.4 ? 2.3%,
59.4 ? 16.5%, respectively; treatment of PBS with MMC
showed cell viability of 94.9 ? 3.9% (Figure 1). Among all
the CHM tested, BZYQT exhibited the most pronounced
effect on the enhancement of MMC-induced cytotoxicity.
Combination of BZYQT and MMC on the induction of
apoptosis
We next assessed whether the enhanced cytotoxicity to
MMC by BZYQT was due to apoptosis induction. Apop-
tosis was evaluated by quantitative fluorescent microscopy
of the nuclear changes with bisbenzimide trihydrochloride
(Hoechst-33258) staining of condensed nuclear chromatin.
MKN-74 cells were treated with PBS or BZYQT for 48 h.
Subsequently MMC (either 0.25 or 1.0 μg/ml) was added
to the media for another 24 h of incubation. Cells exposed
to BZYQT and MMC did not show significant increase in
apoptosis induction when compared to PBS and MMC
(Figure 2A). Using ELISA for DNA fragmentation as
another independent assay for apoptosis measurement,
we confirmed the findings from quantitative fluorescent
microscopy (Figure 2B). Thus the enhanced cytotoxicity
from BZYQT and MMC was not due to induction of
apoptoic cell death.
Moreover, we explored whether the BZYQT could in-
crease MMC-induced apoptosis if cells were treated with
MMC for 24 h then washed out with subsequent expos-
ure to BZYQT for another 48 h. As shown in Figure 3A,
if cells were exposed to 0.25 μg/ml of MMC for 24 h
followed by exposure to BZYQT for another 48 h, there
was no significant change in MMC-induced apoptosis.
However, in cells treated with 1 μg/ml of MMC followed
by exposure to BZYQT for another 48 h, there was a sig-
nificant decrease in the MMC-induced apoptosis (58.9 ?
5.9% with MMC alone vs. 44.7 ? 6.1% with sequentialTable 1 Cytotoxicity of chinese herbal medicine on
MKN-74 cells
IC10 (mg/ml) IC50 (mg/ml)
BZYQT 0.8 ? 0.1 2.4 ? 0.6
BYT 0.43 ? 0.0 3.9 ? 0.8
JYJ 0.68 ? 0.1 1.8 ? 0.4MMC and BZYQT; P < 0.01). The representative pho-
tomicrographs are shown in Figure 3B. Safingol, an
inhibitor of protein kinase C, which has been shown to
enhance MMC-induced apoptosis in human gastric
cancer cells, was used as a positive control [15].
Discussion
In human gastric adenocarcinoma cell, MMC has been
shown to induce apoptosis by a caspase-dependent
mechanism [16]. Adding PKC inhibitor to MMC further
enhances MMC-induced apoptosis [15]. In this study,
we explored the effects of commonly used CHM formu-
las in cancer patients with MMC in human gastric
cancer cell line, MKN-74. Among these CHM tested:
BZYQT, BYT and JYJ, BZYQT significantly enhanced
MMC induced cytotoxicity against MKN-74 cells. Upon
further investigation, we confirmed that the enhanced
cytotoxicity by BZYQT and MMC was not due to apop-
tosis induction. Studies done on other CHM formulas
such as BYT and JYJ also demonstrated similar results
(data not shown). Thus the enhanced cytotoxicity in
MKN-74 cells with the combination of CHM and MMC
is most likely mediated by necrosis-like cell death.
Necrosis is one type of cell death, which is distinct
from apoptosis [17]. During necrosis, cells first swell
followed by collapse of plasma membranes collapse, sub-
sequently leading to cell lysis. This process can be in-
duced by various stimuli such as infection, trauma,
ischemia and toxin. Apoptosis, on the other hand, is a
process of programmed cell death, occurring during
Figure 2 Effect of combination BZYQT with MMC on induction
of apoptosis. MKN-74 cells were treated with 0.82 mg/ml of BZYQT
for 48 h. Then 0.25 or 1.0 μg/ml MMC was added for another 24 h. (A)
Cells were counted and scored for apoptoic chromatin condensation
by the quantitative fluorescence microscopy. Bars represent mean ?
SD of cells with apoptosis counted as a percentage of 400 total
cells randomly counted in duplicate samples. (B) Apoptotic cell
death was evaluated by quantitative by DNA fragmentation by
using single-strand DNA ELISA kit. Values are expressed as mean ?
SD from three separate experiments.
Figure 3 Effect of pre-treated with MMC followed by exposure
to BZYQT on induction of apoptosis. (A) MKN-74 cells were treated
with 0.25 or 1.0 μg/ml MMC for 24 h. Subsequently, cells were washed
and treated with or without 0.82 mg/ml of BZYQT for 48 h. Cells were
counted and scored for apoptoic chromatin condensation by the
quantitative fluorescence microscopy. Bars represent mean ? SD of
cells with apoptosis counted as a percentage of 400 total cells randomly
counted in duplicate samples. **P <0.01 compared with untreated
control group. #P < 0.01 compared each other. (B) Photomicrographs
of representative fields of MKN-74 cells stained with bisbenzimide
trihydrochloride (Hoescht-33258) to evaluate nuclear chromatin
condensation after treatment with no drug (panel A), 1.0 μg/ml
MMC for 24 h then cells were washed followed by incubation with
no drug for 48 h (panel B), 1.0 μg/ml MMC for 24 h then cells were
washed followed by exposure to 0.82 mg/ml of BZYQT for 48 h
(panel C), no drug for 48 h prior to 50 μM safingol combined with
1.0 μg/ml MMC for 24 h (panel D).
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During apoptosis, there is extensive blebbing of cell mem-
brane followed by chromatin condensation and chromo-
somal DNA fragmentation.
It has been reported that intracellular ATP level is a
determinant factor to induce necrosis-like cell death
[18]. Depletion of ATP results in necrotic cell death, and
blocks apoptosis signaling [19]. We speculate that treat-
ment of BZYQT in MKN-74 might have led to depletion
of intracellular ATP, and then necrotic cell death in-
duced by MMC. BZYQT has been shown to induce
apoptosis in human hepatoma cell lines, and the IC50
values for different hepatoma cell lines were ranged from
0.43 to 2.28 mg/ml [12]. In this study, the IC50 ofBZYQT in MKN-74 gastric cancer cell line was 2.4 ?
0.6 mg/ml, which was in the similar range as in the
hepatoma cell lines. However, the enhanced MMC-induced
cytotoxicity by BZYQT in MKN-74 was not mediated
through apoptoic cell death. Thus, the cell death pathway
elicited by BZYQT may be cell line dependent. Our find-
ings warrants further confirmation in other cancer cell lines
as well in animal studies.
Some compounds in BZYQT such as astragaloside,
ginsenoside, saikosaponin and glycyrrhizin have been
confirmed antitumor activity [20-23]. It remains to be
Kuo et al. Biomarker Research  (2014) 2:26 Page 5 of 5determined which compound in BZYQT is the active
driver for cytotoxicity in gastric cancer cells. It is essen-
tial to identify the interaction of CHM with commonly
used anticancer therapeutics including biological agents
in gastric cancer and other cancer types. In our study,
we have found if cancer cells were exposed to MMC
first, followed by BZYQT, there were less MMC-induced
apoptosis as compared to initial exposure of BZYQT
followed by MMC. Thus the sequence of administration
schedule for CHM and chemotherapy may alter cytotox-
icity and apoptosis induction, and requires further investi-
gation. The findings from this study provide a rationale
for further exploration in this aspect.
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